Powered By
Lumvoa (veligrotug-vvze) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with thyroid eye disease (TED).
Lumvoa is a type of medicine called a monoclonal antibody. It works by attaching to a protein called insulinlike growth factor-1 receptor (IGF-1R) and blocking signals through that protein. Exactly how Lumvoa works to treat TED is not fully understood.
Doctors prescribe Lumvoa when a person needs treatment for TED, regardless of how active the disease is or how long they’ve had it.
Lumvoa is given by intravenous (IV) infusion.
The recommended dose of Lumvoa for TED is 10 milligrams per kilogram of body weight, given by IV infusion every three weeks for a total of 5 infusions. This dose is based on body weight, which is a standard way healthcare providers calculate how much medicine a person should receive.
The first infusion is usually given over 45 minutes. Later infusions may be given over at least 30 minutes if well tolerated.
This information is based on prescribing information, but your healthcare provider may tailor your treatment plan. Always follow their guidance.
In clinical studies of Lumvoa for TED in adults, the most common side effects occurred in about 6 percent to 40 percent of people. They included:
Lumvoa can cause serious side effects that may require immediate medical attention. These include:
Get medical help right away if you think you are having a serious reaction.
Viridian Therapeutics, the manufacturer of Lumvoa, offers the ViridianCares Co-Pay Program. Eligible people with commercial insurance may pay as little as $0 in out-of-pocket costs.
To learn more, visit the Lumvoa getting-started page or call 866-822-7371, Monday through Friday, 8 a.m. to 8 p.m. ET.
Tell your doctor if you have any allergies to Lumvoa or any of its ingredients.
Tell your doctor about all medicines you take, including prescription drugs, over-the-counter medicines, and supplements.
Before receiving Lumvoa, tell your doctor if you:
If you are pregnant, planning to become pregnant, or breastfeeding, talk with your doctor about the risks and benefits of Lumvoa. Lumvoa may harm a fetus. If you can become pregnant, use effective birth control before starting treatment, during treatment, and for six months after your last dose of Lumvoa.
These answers are fact-checked by our editorial staff.
How effective is Lumvoa?
In studies of people with thyroid eye disease, 70 percent of those with active disease and 57 percent of those with chronic disease had at least a 2-millimeter reduction in eye bulging by week 15, without an increase of 2 millimeters or more in the other eye. This compared with 5 percent and 8 percent, respectively, of people who received a placebo (an inactive treatment).
Among people who had this improvement by week 15, 71 percent with active disease and 57 percent with chronic disease still had the improvement at week 52. Among people whose double vision went away by week 15, 50 percent with active disease and 80 percent with chronic disease were still free of double vision at week 52.
What tests or monitoring are needed with Lumvoa for thyroid eye disease?
Your healthcare provider should check your hearing before, during, and after treatment with Lumvoa. Blood sugar levels and signs of high blood sugar should also be checked before infusions and monitored during treatment. If high blood sugar develops during treatment, monitoring should continue after treatment ends.
Your healthcare provider should also watch for signs and symptoms of inflammatory bowel disease.
On TEDhealthteam, people share their experiences with thyroid eye disease, get advice, and find support from others who understand.
Learn more about Lumvoa and thyroid eye disease care:
More resources from TEDhealthteam that mention Lumvoa
Become a member to get even more
Join
Your Privacy Choices
